I

Instituto Oncologico de Cordoba | Cordoba, Argentina

Research site

(Unclaimed)

Location

Parana 560 2 piso, Cordoba, Cordoba, Argentina

Site insights

Top conditions

Top treatments

Nivolumab

BMS-936558

Anastrozole

Docetaxel

Exemestane

Tamoxifen

Ipilimumab

Bevacizumab

Dacarbazine

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 9 total trials

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It...

Enrolling

Urothelial Carcinoma

Drug: pembrolizumab

Drug: disitamab vedotin

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal...

Invitation-only

Breast Cancer

Drug: Exemestane Tablets

Drug: Anastrozole Tablets